Interactions between lunesta(eszopiclone) and Atazanavir (atazanavir)
atazanavir and eszopiclone (Moderate Drug-Drug)
ADJUST DOSE: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eszopiclone (the S-enantiomer of zopiclone), which is primarily metabolized by the isoenzyme. According to product labeling, coadministration of eszopiclone (3 mg) with the potent CYP450 3A4 inhibitor ketoconazole (400 mg daily for 5 days) resulted in a 2.2-fold increase in systemic exposure (AUC) to eszopiclone. Peak plasma concentration (Cmax) and half-life were increased 1.4-fold and 1.3-fold, respectively. Theoretically, this interaction should also affect racemic zopiclone.
MANAGEMENT: The dosage of eszopiclone and zopiclone should be reduced when used with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, voriconazole, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.
